The Hidden Conversation in Our Cells

How Receptor Chatter Could Revolutionize Fibrosis Treatment

Article Navigation

Fibrosis—the destructive scarring of tissues—contributes to nearly 45% of deaths in the industrialized world. When kidneys, hearts, or lungs succumb to this slow-motion stranglehold of collagen, patients face limited therapeutic options. But recent breakthroughs reveal an unexpected molecular conversation between three cellular receptors that could unlock new approaches to treating fibrosis. This story begins with a hormone therapy paradox and ends with a fundamental rewrite of how we view cell signaling in scar-forming cells called myofibroblasts 1 .

The Cast of Characters: Meet the Receptors

To appreciate this discovery, we must first meet the key players:

AT1R (Angiotensin II Type 1 Receptor)

The "villain" of tissue scarring. When activated by angiotensin II (AngII), it triggers inflammation and fibrosis. Blockers of this receptor—like losartan or candesartan—are frontline drugs for hypertension and kidney protection 4 5 .

AT2R (Angiotensin II Type 2 Receptor)

AT1R's benevolent counterpart. It counters AT1R's effects by promoting blood vessel dilation and reducing fibrosis. Experimental drugs like Compound 21 (C21) selectively target AT2R 5 .

RXFP1 (Relaxin Family Peptide Receptor 1)

The receptor for serelaxin, a hormone with potent antifibrotic properties. It activates pathways that dissolve excess collagen and inhibit scar-forming cells 1 7 .

For years, these receptors were studied in isolation. But in 2019, researchers discovered they form a tripartite signaling network within myofibroblasts—the collagen-producing cells responsible for fibrosis. When these receptors physically interact, their behavior changes dramatically 1 6 .

The Paradox: When Blocking a "Bad" Receptor Backfires

The breakthrough emerged from an apparent contradiction. Researchers treated fibrotic kidneys and hearts with serelaxin, expecting its known antifibrotic effects. But when combined with AT1R blockers (ARBs like irbesartan or candesartan), serelaxin stopped working. Instead of enhanced protection, the ARBs abolished serelaxin's benefits 1 .

Key Insight

AT1R blockers disrupt communication between RXFP1 and AT2R—receptors essential for serelaxin's action. This explains why combining these drugs may be counterproductive 2 .

Table 1: Key Receptors in Myofibroblasts and Their Roles
Receptor Primary Agonist Function Expression in Fibrosis
AT1R Angiotensin II Pro-fibrotic, inflammatory Increased
AT2R Angiotensin II Anti-fibrotic, tissue repair Dramatically upregulated
RXFP1 Serelaxin Collagen degradation, TGF-β inhibition Constitutively expressed

Decoding the Experiment: How the Receptor Trio Was Unmasked

The landmark 2019 study employed a multi-pronged approach across cells, tissues, and animal models 1 2 6 :

  • Human cardiac myofibroblasts and rat renal myofibroblasts were treated with serelaxin alone or with ARBs (irbesartan/candesartan).
  • Result: ARBs blocked serelaxin's suppression of collagen and α-SMA (a myofibroblast marker).

  • Using fluorescence resonance energy transfer (FRET), researchers confirmed AT1R and RXFP1 form physical complexes on cell membranes—even without AngII.
  • Result: Serelaxin doesn't bind AT1R, but RXFP1-AT1R interactions alter how signals pass between receptors 6 .

Three animal models of fibrosis were used:

  1. Kidney fibrosis (unilateral ureteric obstruction)
  2. Heart fibrosis (isoprenaline-induced cardiomyopathy)
  3. Salt-induced hypertension

Mice received:

  • Serelaxin alone
  • Candesartan alone
  • Serelaxin + candesartan
Table 2: Antifibrotic Effects in Kidney and Heart Models
Treatment Collagen Reduction (Kidney) Collagen Reduction (Heart) Myofibroblast Suppression
Serelaxin 62% 58% Yes
Candesartan 28% 24% Partial
Serelaxin + Candesartan 0% 3% No

Result: Candesartan completely blocked serelaxin's antifibrotic effects in both organs. This was not a kidney-specific phenomenon—it reflected a fundamental signaling crosstalk 2 .

  • Antagonists targeting each receptor (AT1R, AT2R, or RXFP1) disrupted signals from the others.
  • Key insight: The receptors act as an integrated triad. Blocking one allosterically alters the others' behavior 1 6 .

The Scientist's Toolkit: Key Reagents in Fibrosis Research

Table 3: Essential Tools for Decoding Receptor Crosstalk
Reagent Function Key Study Use
Serelaxin Recombinant human relaxin-2; activates RXFP1 Tested antifibrotic actions in cells and mice
Compound 21 (C21) Selective AT2R agonist Probed AT2R's role independent of AngII
Candesartan/Irbesartan AT1R blockers (ARBs) Disrupted RXFP1-AT2R crosstalk
PD123319 AT2R antagonist Confirmed AT2R's role in serelaxin signaling
Osmotic minipumps Sustained drug delivery Administered serelaxin/ARBs in vivo (weeks)
FRET imaging Detects protein-protein interactions Visualized AT1R-RXFP1 complexes in live cells

Therapeutic Implications: Why This Changes Everything

This triad interaction has profound clinical implications:

ARBs may hinder new antifibrotics

While ARBs remain valuable for blood pressure control, combining them with RXFP1 or AT2R agonists (e.g., serelaxin or C21) could blunt efficacy. This explains past clinical trial failures where serelaxin underperformed in patients on ARBs 1 .

New targets for drug design
  • Heteromer-specific drugs: Molecules that stabilize the AT2R-RXFP1 interaction could enhance antifibrotic signaling.
  • Allosteric modulators: Compounds that "tune" receptor crosstalk without fully blocking any single receptor 6 .
Beyond heart and kidney

This mechanism likely extends to liver and lung fibrosis, where myofibroblasts drive collagen deposition 1 .

The Future: Drugs That Listen to the Conversation

The next frontier is developing therapies that exploit, rather than disrupt, this receptor dialogue. Early approaches include:

  • Biased agonists for RXFP1 that favor antifibrotic signaling.
  • AT2R-RXFP1 co-activators designed to strengthen their partnership against AT1R 4 6 .

"We've moved from seeing receptors as isolated switches to understanding them as social networks. The future lies in designing drugs that respect these conversations."

Lead researcher in the study 3

This story exemplifies how scientific paradoxes—like a beneficial drug blocking another's effect—can reveal hidden biological worlds. In the chatter between AT1R, AT2R, and RXFP1, we've found a language that may finally let us speak the command: "Heal, but do not scar."

References